IMCR - Immunocore posts data from late-stage melanoma study at AACR21

Immunocore (IMCR) announces positive data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice in first-line metastatic uveal melanoma ((mUM)) in the clinical trial plenary session at the American Association for Cancer Research ((AACR)) Annual Meeting 2021.Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye, with up to 50% of people with the condition eventually developing metastatic disease.Tebentafusp showed a statistically significant and clinically meaningful improvement in overall survival ((OS)) as a first-line treatment in mUM.The OS Hazard Ratio (((HR)) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine).Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function.Shares up more than 3% post market.#AACR21

For further details see:

Immunocore posts data from late-stage melanoma study at AACR21